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Abstract
Background
Several common genetic variants have been associated with either ventricular fibrillation
(VF) or sudden cardiac death (SCD). However, replication efforts have been limited. There-
fore, we aimed to analyze whether such variants may contribute to VF caused by first ST-
elevation myocardial infarction (STEMI).
Methods
We analyzed 27 single nucleotide polymorphisms (SNP) previously associated with SCD/
VF in other cohorts, and examined whether these SNPs were associated with VF caused by
first STEMI in the GEnetic causes of Ventricular Arrhythmias in patients with first ST-eleva-
tion Myocardial Infarction (GEVAMI) study on ethnical Danes. The GEVAMI study is a pro-
spective case-control study involving 257 cases (STEMI with VF) and 537 controls (STEMI
without VF).
Results
Of the 27 candidate SNPs, one SNP (rs11720524) located in intron 1 of SCN5A which was
previously associated with SCD was significantly associated with VF caused by first STEMI.
The major C-allele of rs11720524 was present in 64% of the cases and the C/C genotype
was significantly associated with VF with an odds ratio (OR) of 1.87 (95% CI: 1.12–3.12;
P = 0.017). After controlling for clinical differences between cases and controls such as age,
sex, family history of sudden death, alcohol consumption, previous atrial fibrillation, statin
use, angina, culprit artery, and thrombolysis in myocardial infarction (TIMI) flow, the C/C
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genotype of rs11720524 was still significantly associated with VF with an OR of 1.9 (95% CI:
1.05–3.43; P = 0.032). Marginal associations with VF were also found for rs9388451 in
HEY2 gene. The CC genotype showed an insignificant risk for VF with OR = 1.50 (95% CI:
0.96–2.40; P = 0.070).
Conclusion
One common intronic variant in SCN5A suggested an association with VF caused by first
STEMI. Further studies into the functional abnormalities associated with the noncoding vari-
ant in SCN5A may lead to important insights into predisposition to VF during STEMI.
Introduction
Coronary artery disease and its ultimate consequence, myocardial infarction (MI), are believed
to underlie 75% of the deaths of patients who experience sudden cardiac death (SCD).[1–3] It
is also estimated that SCD accounts for 30 to 50% of all coronary deaths.[4] SCD is a major
challenge for the clinician because most episodes occur in individuals without previously iden-
tified cardiac disease.[5,6] The pathophysiology of SCD caused by MI is complex. It is believed
to involve an interaction between underlying disease and a transient event, such as acute myo-
cardial ischemia, which results in electrical instability and ventricular fibrillation (VF).[2] VF
is a life-threatening complication and occurs in nearly 12% of patients with first ST-segment
elevation myocardial infarction (STEMI).[7,8] Therefore, efforts to improve risk stratification
for SCD should in part be based on an understanding of the molecular mechanisms and path-
ways underlying the occurrence of VF.[9] In the GEnetic causes of Ventricular Arrhythmias in
patients with first ST-elevation Myocardial Infarction (GEVAMI) study on ethnical Danes[7]
and the Dutch AGNES (Arrhythmia Genetics in the NEtherlandS Study) study[10] both sug-
gested a possible genetic component to VF since patients with a family history of sudden death
among first-degree relatives had significantly higher odds of experiencing VF before primary
percutaneous coronary intervention (PPCI). In the AGNES study, a common genetic variant
at 21q21 (rs2824292, odds ratio (OR) = 1.78, 95% CI 1.47–2.13, P = 3.3x10-10) was found to
be associated with VF before PPCI in STEMI patients in a genome-wide association study
(GWAS).[11] The rs2824292 is located upstream of CXADR gene which encodes the coxsackie
and adenovirus receptor (CAR), a transmembrane cell adhesion molecule predominantly
located at the intercalated disc between cardiomyocytes.[12] However, this association has yet
to be replicated in a larger cohort. There have also been several other variants reported to be
associated with SCD, primarily from candidate gene studies with limited replication.[9] There-
fore, we aimed to determine whether the 21q21variant, as well as other variants previously
associated with SCD, would be associated with underlying susceptibility to VF due to first
STEMI in the GEVAMI case-control study.
Methods
Study population
The GEVAMI study is an ongoing nationwide prospective Danish case-control study among
patients with first STEMI between the ages of 18 and 80 years.[7] Cases are patients who expe-
rienced onset of VF within the first 12 hours of symptoms of STEMI before guided catheter
insertion for PPCI, and controls did not have VF during this time period or during PPCI.
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Cases and controls are collected at all four PCI centers in Denmark. Cases and controls were
required to have cardiac symptoms lasting12 hours, acute STEMI on ECG, and a plan to
proceed with for acute PPCI. Baseline demographics and previous medical history are col-
lected by research coordinators utilizing pre-designed questionnaires and whole blood is col-
lected for genetic analysis. Follow-up on the patients is done by the Danish registries.
Ethics statement
Signed informed consent is available for all patients enrolled in this study. Procedures are in
accordance with the ethical standards of the national ethics committee (protocol number: H-
3-2010-133) on human research and with the Helsinki Declaration of 1975, as revised in 1983.
Permission from the Danish Data Protection Agency was also obtained before the study was
initiated (Jr.nr. 2010-41-5688). The study was conducted according to the guidelines of The
National Committee on Health Research Ethics, Denmark.
DNA extraction and SNP genotyping
In brief, total genomic DNA was isolated from whole blood samples using LGC’s Kleargene™
silica-based DNA extraction, performed at LGC Genomics. Isolated DNA was analyzed using
UV spectrophotometry to estimate both the quality and quantity of the DNA and normalized.
Based upon the results of previous genetic association studies, 27 common genetic variants
known to associate with VF/SCD[2,9,11,13–16,16–25] were selected for SNP genotyping in the
cases and controls. SNP genotyping was performed using KASP™ genotyping assays from LGC
genomics (http://www.lgcgenomics.com). For each putative varietal SNP, two allele-specific
forward primers and one common reverse primer were designed (LGC Genomics, Hoddes-
don, UK). KASP genotyping assays are based on competitive allele-specific PCR and enable
biallelic scoring of SNPs at specific loci. The SNP-specific KASP Assay mix and the universal
KASP Master mix are added to DNA samples, a thermal cycling reaction is then performed,
followed by an end-point fluorescent read. Bi-allelic discrimination is achieved through the
competitive binding of two allele-specific forward primers, each with a unique tail sequence
that corresponds with two universal FRET (fluorescence resonant energy transfer) cassettes;
one labelled with FAM™ dye and the other with HEX™ dye. All assays were conducted without
knowledge of case status, and samples were labeled by study code only. Genotypes for all SNPs
passed our quality-control threshold (call-rate94%; Hardy-Weinberg equilibrium P>0.05 in
control subjects).
Statistical analysis
Medians or proportions of baseline and presenting characteristics in Table 1 were computed
for cases and controls, and significance of associations were tested using the Wilcoxon
rank-sum test for continuous variables and the χ2 test or Fisher exact test (where appropri-
ate) for categorical variables. A two-tailed p value0.05 was considered statistically signifi-
cant. An age and sex-adjusted logistic regression model were constructed to estimate OR for
the association between each SNP and VF using an additive model of inheritance. Any SNPs
which were significantly associated with VF were also adjusted for clinical differences
between cases and controls such as family history of sudden death, alcohol consumption,
previous atrial fibrillation, statin use, angina, culprit artery, and thrombolysis in myocardial
infarction (TIMI) flow.[7] We considered each SNP as a single hypothesis however a Bon-
ferroni correction for multiple testing was used to assess the association of single SNP with
VF. Homozygote risk allele and adjusted odds ratios are presented in Table 2. Per copy risk
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Table 1. Baseline characteristics of the cohort.
Variables Cases (n = 257) Controls (n = 537) P-value
Cardiovascular risk profile
Female sex, No. (%) 35 (14) 131 (25) 0.001
Median Age at index infarction, y (IQR†) 60 (53–68) 61 (52–66) 0.100
Body mass index (kg/m2), (IQR) 27.2 (25–29) 26.7 (24–29) 0.400
Smoking (pack year), (IQR) 25 (5–41) 25 (6–42) 0.200
Smoking, No. (%)
Never 38 (16) 108 (20) 0.300
Past 69 (28) 133 (25)
Current 136 (56) 290 (55)
Alcohol per week, (unit‡, IQR) 6 (1–15) 3 (0–9) <0.001
Alcohol units per week (categorized), No. (%)
Non-drinkers 46 (19) 143 (27) <0.001
Normal (1–7) 90 (38) 242 (46)
Moderate High (8–14) 41 (17) 70 (13)
High (>15) 60 (26) 73 (14)
Diabetes, No. (%) 30 (12) 47 (9) 0.200
Hypertension, No. (%) 102 (41) 184 (35) 0.070
COPD§, No. (%) 12 (5) 30 (6) 0.700
Hypercholesterolemia, No. (%) 97 (39) 165 (31) 0.023
Stroke, No. (%) 18 (7) 26 (5) 0.200
Atrial fibrillation, No. (%) 16 (7) 10 (2) 0.006
Depression, No. (%) 28 (11) 65 (12) 0.700
Epilepsy, No. (%) 4 (2) 5 (1) 0.500
Family History of, No. (%)
Sudden death 94 (40%) 128 (25%) <0.001
Myocardial infarction 90 (40%) 195 (38%) 0.600
Stroke 36 (16%) 75 (15%) 0.600
Medication before STEMI, No. (%)
β-blockers 20 (8) 43 (8) 0.900
Statins 55 (22) 65 (12) <0.001
ACE/ARB# blockers 50 (21) 90 (17) 0.200
Aspirin 28 (12) 40 (8) 0.060
Procedural characteristics, No. (%)
Infarct location
Anterior 136 (57) 103 (43) 0.001
Non-anterior 213 (43) 280 (57)
Preprocedural TIMI flows, No. (%)
TIMI 0 137 (57) 240 (49) 0.017
TIMI I 17 (7) 50 (10)
TIMI II 23 (9) 83 (17)
TIMI III 64 (27) 117 (24)
Postprocedural TIMI flows, No. (%)
TIMI 0 8 (3) 7 (1) 0.080
TIMI I 0 (0) 0 (0)
TIMI II 12 (5) 14 (3)
TIMI III 220 (92) 469 (96)
Cardiac Symptoms Within 1 Year Prior to STEMI, No. (%)
(Continued )
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Table 1. (Continued)
Variables Cases (n = 257) Controls (n = 537) P-value
Angina 117 (49) 313 (64) <0.001
Dyspnea 55 (24) 127 (26) 0.500
Palpitations 17 (7) 46 (9) 0.400
Syncope 4 (2) 5(1) 0.500
IQR†: interquartile range; unit‡ of alcohol = 12gram (1 drink); COPD§: chronic obstructive pulmonary disease; ACE/ARB#: angiotensin-converting-enzyme
inhibitor/ angiotensin II receptor blocker. TIMI: thrombolysis in myocardial infarction
doi:10.1371/journal.pone.0170193.t001
Table 2. Homozygote genotype of inheritance for association of 27 SNPs previously associated with sudden cardiac death and in this study inves-
tigated for association with ventricular fibrillation before ST-segment elevation myocardial infarction.
Chr† SNP‡ Nearest Gene Homozygote Risk Allele OR§ 95% CI* P-value#
1 1 rs10918859 NOS1AP AA 1.01 0.47–2.18 0.970
2 1 rs12084280 NOS1AP CC 1.90 0.26–13.70 0.500
3 1 rs16847548 NOS1AP CC 0.86 0.38–1.93 0.720
4 1 rs17500488 CASQ2 CC 1.13 0.10–13.04 0.920
5 1 rs3010396 CASQ2 AA 0.89 0.57–1.38 0.600
6 1 rs7366407 CASQ2 AA 0.71 0.33–1.52 0.380
7 1 rs12090554 HMCN1 CC 0.76 0.34–1.68 0.500
8¶ 2 rs4665058 BAZ2B AA - - -
9 2 rs6730157 RAB3GAP1 GG 1.43 0.80–2.57 0.220
10 3 rs11720524 SCN5A CC 1.87 1.12–3.12 0.017
11 3 rs11708996 SCN5A CC 1.03 0.40–2.63 0.940
12 3 rs41312391 SCN5A AA 0.39 0.13–1.17 0.094
13¶ 3 rs6795970 SCN10A AA - - -
14 3 rs10428132 SCN10A TT 1.00 0.61–1.61 0.990
15 3 rs9862154 GPD1L GG 1.03 0.47–2.28 0.920
16¶ 4 rs2200733 PITX2 TT - - -
17¥ 5 rs7737692 LPCAT1 GG - - -
18 5 rs1042714 ADRB2 GG 0.97 0.62–1.52 0.913
19 6 rs9388451 HEY2 CC 1.50 0.96–2.40 0.070
20 8 rs10503929 NRG1 CC 0.92 0.39–2.16 0.850
21 9 rs10757274 CDKN2A/2B GG 1.15 0.73–1.81 0.525
22 9 rs2383207 CDKN2A/2B AA 0.76 0.48–1.20 0.250
23 9 rs1353342 PCSK5 AA 2.73 0.60–12.40 0.190
24 10 rs2077316 ZNF365 GG 1.44 0.23–8.88 0.690
25 11 rs2283222 KCNQ1 CC 1.48 0.90–2.40 0.120
26 13 rs3864180 GPC5 GG 0.68 0.36–1.03 0.130
27 21 rs2824292 CXADR GG 0.77 0.47–1.26 0.300
Chr†: chromosome; SNP‡: single-nucleotide polymorphism; OR§: odds ratio; CI*: confidence interval; P value# for the additive genetic model of inheritance.
¶: No homozygote risk allele exists in our cohort.
¥: No signal at all (repeated 3 times). Logistic regression models under an additive model of inheritance adjusted for age and sex. OR for the homozygote
risk allele is shown in the table. Number of cases = 257; number of controls = 537.
doi:10.1371/journal.pone.0170193.t002
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allele frequency is provided in Table 3. All analyses were performed using the Stata software
package version 12.0 (StataCorp).
Results
Clinical characteristics of the cohort
A total of 257 cases (35 women and 222 men) with VF caused by STEMI and 537 (131 women
and 426 men) STEMI controls without VF were included in this prospective study. The clinical
characteristics at the time of STEMI are shown in Table 1. The median age of the cases was 60
(interquartile range (IQR); 53–68) years and for the controls 61 (IQR; 52–66) years. Compared
to the control group, the case group was more likely to be male, have a history of atrial fibrilla-
tion (AF) or hypercholesterolemia, and a family history of sudden death as reported previously.
[7] Furthermore, the proportion on statin therapy was higher in the case group compared to
Table 3. Additive genetic model of inheritance (per copy allele frequency) for association of 27 SNPs previously associated with sudden cardiac
death, and in this study investigated for association with ventricular fibrillation before ST-segment elevation myocardial infarction.
Chr† SNP‡ Nearest Gene (References) RAF§ Associated Allele Frequency (Cases/Controls) OR* 95% CI# P-value
1 1 rs10918859 NOS1AP[24] A 0.17/0.20 0.78 0.59–1.04 0.090
2 1 rs12084280 NOS1AP[24] C 0.07/0.08 0.94 0.62–1.41 0.800
3 1 rs16847548 NOS1AP[22] C 0.21/0.22 0.93 0.71–1.22 0.600
4 1 rs17500488 CASQ2[24] C 0.07/0.07 1.10 0.72–1.65 0.700
5 1 rs3010396 CASQ2[24] A 0.43/0.45 0.93 0.75–1.17 0.600
6 1 rs7366407 CASQ2[24] A 0.23/0.26 0.90 0.67–1.20 0.500
7 1 rs12090554 HMCN1[11] C 0.18/0.20 0.88 0.67–1.16 0.400
8¶ 2 rs4665058 BAZ2B[17] A 0.00/0.00 - - -
9 2 rs6730157 RAB3GAP1[21] G 0.26/0.23 1.12 0.88–1.43 0.400
10 3 rs11720524 SCN5A[14] C 0.64/0.58 1.25 0.99–1.57 0.050
11 3 rs11708996 SCN5A[13] C 0.15/0.16 1.00 0.75–1.34 1.000
12 3 rs41312391 SCN5A[25] A 0.17/0.18 0.94 0.70–1.25 0.700
13¶ 3 rs6795970 SCN10A[13] A 0.00/0.00 -
14 3 rs10428132 SCN10A[13] T 0.37/.038 1.00 0.90–1.24 0.900
15 3 rs9862154 GPD1L[24] G 0.22/0.20 1.10 0.85–1.45 0.400
16¶ 4 rs2200733 PITX2[25] T 0.08/0.08 0.96 0.65–1.42 0.900
17¥ 5 rs7737692 LPCAT1[19] G -/- - - -
18 5 rs1042714 ADRB2[15,23] G 0.42/0.42 1.01 0.81–1.25 0.900
19 6 rs9388451 HEY2[13] C 0.54/0.49 1.20 0.97–1.50 0.090
20 8 rs10503929 NRG1[20] C 0.18/0.20 0.92 0.69–1.20 0.500
21 9 rs10757274 CDKN2A/2B[16] G 0.50/0.49 1.08 0.86–1.35 0.500
22 9 rs2383207 CDKN2A/2B[16] A 0.45/0.48 0.87 0.70–1.10 0.300
23 9 rs1353342 PCSK5[11] A 0.12/0.10 1.14 0.80–1.66 0.400
24 10 rs2077316 ZNF365[21] G 0.06/0.07 0.97 0.63–1.49 0.900
25 11 rs2283222 KCNQ1[14] C 0.34/0.30 1.18 0.94–1.47 0.100
26 13 rs3864180 GPC5[18] G 0.37/0.40 0.89 0.71–1.10 0.300
27 21 rs2824292 CXADR[11] G 0.49/0.54 0.93 0.75–1.18 0.600
Chr†: chromosome; SNP‡: single-nucleotide polymorphism; RAF§: Risk allele frequency in cases over controls in our cohort; OR*: odds ratio; CI#:
confidence interval; P value for the additive genetic model of inheritance (per copy allele frequency). Logistic regression models under an additive model of
inheritance adjusted for age and sex. Number of cases = 257; number of controls = 537.
¶: No homozygote risk allele exists in our cohort.
¥: No signal at all (repeated 3 times).
doi:10.1371/journal.pone.0170193.t003
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the control group, likely due to the higher degree of hypercholesterolemia in the case group
(Table 1). Median levels of average weekly alcohol intake were higher in the case group (6
units/week) as compared to the control group (3 units/week) without VF (P = 0.001). Cases did
not differ significantly from the controls with respect to other cardiovascular risk factors such
as smoking, diabetes, and hypertension.
Genotyping
A panel of 27 SNPs was genotyped in 794 individuals (Table 2). The overall call rate was
94%. Homozygote risk allele and the results of the case-control association are presented in
Table 2. The strongest association was observed for the rs11720524 SNP which is located in
intron 1 of SCN5A near the promoter region. The homozygous C/C genotype of rs11720524
was associated with VF with an OR of 1.87 (95% CI: 1.12–3.12; P = 0.017) (Table 3). After
controlling for clinical differences between cases and controls such as age, sex, family
history of sudden death, alcohol consumption, previous atrial fibrillation, statin use, angina,
culprit artery, and thrombolysis in myocardial infarction (TIMI) flow, the C/C genotype of
rs11720524 was still significantly associated with VF with an OR of 1.9 (95% CI: 1.05–3.43;
P = 0.032) (not shown in the table). Even though we tested each SNP as a single hypothesis, the
rs11720524 SNP was not associated with VF after Bonferroni correction.
The risk allele frequencies for each SNP and the results from logistic regression analysis
adjusted for age and sex under additive genetic model of inheritance (per copy allele fre-
quency) are presented in Table 3. Each increasing copy of the major C-allele (per allele risk)
of rs11720524 was borderline associated with VF with an OR of 1.25 (95% CI: 0.99–1.57;
P = 0.050) (Table 3). The call rate for the rs11720524 SNP was 94.2%.
Furthermore, the rs9388451 SNP which is a non-coding SNP and is near the HEY2 gene
showed trend for association with VF. Each increasing copy of the risk allele C-allele (per allele
risk) of rs9388451 was borderline associated with VF with an OR of 1.20 (95% CI: 0.97–1.50;
P = 0.090) (Table 2) and the homozygous CC genotype showed an insignificant increase risk
for VF with OR = 1.50 (95% CI: 0.96–2.40; P = 0.070) (Table 3).
The common genetic variant at 21q21 (rs2824292) previously associated with VF before
PPCI in STEMI patients in the AGNES study[11] was not replicated in the present GEVAMI
study (OR = 0.93; 95% CI: 0.75–1.18; P = 0.600) (Table 2).
For two SNPs (rs4665058 and rs6795970), a homozygote risk allele (A/A and G/G, respec-
tively) did not exists in our cohort although the average call-rate was 97.8% for the two SNPs.
We were not able to genotype the SNP rs7737692 even after 3 times replication. No other
SNPs were associated with VF (Tables 2 and 3).
Discussion
In this prospective case-control study in Denmark we identified a common variant
(rs11720524) located in intron 1 of the SCN5A gene near the promoter region which was asso-
ciated with VF in patients with STEMI. To our knowledge, this is the first study linking a com-
mon variant in SCN5A, the major sodium ion channel in the heart, to VF caused by first
STEMI. Genetic studies have been successful in uncovering rare mutations in ion channel
genes and these have been associated with rare Mendelian arrhythmic disorders, most notably
the long-QT syndrome and to a lesser degree Brugada syndrome,[9,26] and for some of these
disorders genetic testing has become a pivotal part of clinical care.[27,28] In contrast, studies
aimed at identifying genetic risk factors for VF in the setting of MI affecting the majority and
older segment of the population have been sparse[11] and therefore genetic architecture of this
complex and multi-factorial disease largely remains unknown.
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The major C allele of rs11720524 has previously been shown associated to SCD in a com-
bined nested case-control analysis among 516 cases and 1522 matched control subjects of
European ancestry enrolled in 6 prospective cohort studies.[14] Although the associations
between the SNP (rs11720524) and sudden/arrhythmic death were relatively consistent across
the 6 studies, nevertheless this finding required an independent replication study as it was
done in our case-control setup which has a comparable size and is well-phenotyped (VF),
which is necessary to establish certainty regarding the observed association. To support the
association of rs11720524 with VF in our study a recent study also showed an association of
the C/C genotype of the rs11720524 with SCD (OR = 1.351; p = 0.019).[29] Although this asso-
ciation was shown in a highly heterogeneous cardiac death cohort further subgroup analysis
also showed an association of the C/C genotype of the rs11720524 with SCD in chronic ische-
mic heart disease patients (OR = 1.455; p = 0.012). Two other SNPs in SCN5A (rs41312391
and rs11708996) were not associated to VF in the GEVAMI cohort. The SNP rs41312391risk
allele (A) which is also located in the intron near SCN5A has been associated with QT-interval
prolongation in normal subjects in one study (n = 282, P = 0.04).[30] and QT-interval shorten-
ing in another study (n = 396, P = 0.02).[31] Furthermore, in the FinSCDgen Study, Lahtinen
et al. and coworkers showed an association of the SNP rs41312391 risk allele (A) with SCD
with relative risk 1.27 per minor T allele, 95% CI 1.11–1.45, p = 3.4x10-4).[25] The expression
analysis indicated that rs41312391 may change the expression level of a nearby gene, WDR48,
which encodes a WD repeat-containing protein, a regulator of histone deubiquitinating com-
plexes.[25] However, they concluded that SCN5A remains the more likely candidate gene for
SCD due to its known function in cardiac conduction and repolarization. Furthermore, the
SNP rs11708996 has been associated with PR interval (which is an intermediate phenotype of
atrial fibrillation),[32] QT interval[33] and Brugada syndrome.[34] This finding suggests that
the SNP rs11708996 modifying effects are distinct and in the GEVAMI cohort did not predict
risk of VF in STEMI patients.
Identifying the exact causal SNP within the haplotype tagged by (rs11720524) to understand
the underlying genetic mechanism is important and requires functional studies to further
understand the possible role of this gene in the setting of VF. Since SNPs are highly correlated
(in linkage) to the neighboring SNPs and thereby forming haplotypes and presumably these
intronic variants in this halpotypes may exert their influence through the level of expression of
SCN5A. A number of SNPs at the SCN5A and SCN10A locus (Table 2) have been associated
with ECG changes such as QT, RR and QRS interval[9], however our lead SNP (rs11720524)
was not in linkage disequilibrium with any one of these.
The rs9388451 SNP is a non-coding SNP and near the HEY2 gene and encodes a basic
helix-loop-helix transcriptional repressor that is expressed in the cardiovascular system.[35]
Recently, the rs9388451 SNP was shown to be associated with Brugada syndrome and data
indicates that HEY2 regulates cardiac electrical activity in Brugada syndrome by altering the
transcriptional programming during cardiac development.[13] Even though the association of
the (C/C) rs9388451 was not significant (OR = 1.50; P = 0.070), it showed the same trend and
it could be due to lack of power in our analysis.
Several studies[7,10,36] such as our Danish GEVAMI study and the Dutch AGNES study,
showed an association of family history of sudden death with VF caused by first STEMI sug-
gesting a genetic burden of the disease. The AGNES study reported the first GWAS for STEMI
patients with VF before PPCI. In this GWAS study the most significant association with VF
was found at 21q21 (rs2824292, OR = 1.78, 95% CI:1.47–2.13; P = 3.3x10-10).[11] Despite this
novel and important finding, the association of SNP rs2824292 was not detected in the
GEVAMI study nor in a small German case-control study.[7,37] However, there is no obvious
explanation for this disparity. It could be explained by lack of power or maybe the effect of the
A Variant in SCN5A and the Risk of VF Caused by First STEMI
PLOS ONE | DOI:10.1371/journal.pone.0170193 January 13, 2017 8 / 12
risk allele may differ between populations because of gene-gene or gene-environment interac-
tions.[38] Larger sample sizes and homogenous enriched subgroups will be needed to identify
and replicate additional genetic variants associated with VF during STEMI. For instance the
location of the culprit coronary lesion may modify QRS duration and QTc interval and thereby
risk of VF.[9,39] Stratification of VF patients based on culprit lesion may give us a more dis-
crete phenotype, but this requires a very large sample size. An even more discrete phenotype
based on the mechanism of VF (whether it is an immediate VF (phase Ia) or delayed (after the
first 15 minutes) VF (phase Ib)) may also be warranted.[40] This hypothesis is supported by
experimental data comparing wild-type (WT) and heterozygous CAR deficient (CAR+/−)
mice.[39] These data suggested that the burden of VF is much higher in CAR+/− mice with
acute left anterior descending (LAD) occlusion compared to the WT, and this higher VF bur-
den was only observed within the first 15 minutes of acute occlusion of LAD. During later
stages of the ischemic episode, arrhythmia inducibility was not different between WT and
CAR+/− mice.[39]
Lastly, in a combined meta-analysis of GWAS studies of individuals with SCD and control
individuals of European ancestry, a locus at chromosome 2q24.2 (rs4665058) was found to be
associated with SCD[17]; however, this SNP was not associated to VF in the AGNES study or
in the GEVAMI study. These inconsistencies could be caused by heterogeneous underlying
cardiac pathologies of SCD and differing phenotypes (i.e., VF vs. SCD).[9]
The common SNPs associated with VF in the studies mentioned above all by nature had
small effect sizes on risk and are not currently used for clinical management. With the rapid
development of next-generation sequencing technologies, large-scale sequencing projects are
becoming possible allowing the examination of rare genetic variants with larger effects which
could be useful for risk stratification.
We considered each SNP as a single hypothesis but a Bonferroni correction for multiple
testing is often applied in genetic association studies but might be too conservative for highly
selective candidate SNP-based approaches. However, we need to acknowledge that none of the
SNPs would be significant if Bonferroni corrected for multiple testing (P = 0.0019[0.05/27]).
Furthermore, the sample size of 257 VF cases is still fairly low and limits the ability of this
study to find association of common variants with modest effect. It is also important to men-
tion that collecting cases is very time consuming and limited due to relatively low incidence of
VF and difficulties to enroll and collect blood samples in STEMI-patients with VF and cardiac
arrest. This is mostly due to that patients who died outside of the hospital or died in-hospital
prior to enrollment cannot be included. Most of the 27 SNPs reported to be associated with
SCD/VF were identified in patients without acute coronary syndrome, hence may reflect the
underlying pathophysiology of SCD/VF in a more general population rather patients with VF
due to first STEMI.
Finally, our results in this population with white, European/Danish ancestry may not be
generalizable to other populations.
The present study nicely shows that it is often difficult to replicate the genetic associations
observed in previous studies in some other populations. The genetic factors involved in this
complex and multi-factorial disease are still largely unknown; therefore the current study on
all the previous SNPs associated with SCD/VF is important, especially for future direction of
functional studies for more clarification of arrhythmia mechanism and targeted intervention
strategies.
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